Osteosarcoma: Time to move on?

European Journal of Cancer

Volumn 46, Issue 11, 2010, Pages 1942-1945

  Bielack, Stefan S ^a  

^a OLGAHOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; MIFAMURTIDE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILL; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EDITORIAL; FATIGUE; FEVER; HEALTH CARE COST; HUMAN; LIMB SALVAGE; OSTEOSARCOMA; PRIORITY JOURNAL;

EID: 77954219578     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.009     Document Type: Note

References (29)

1. P.A. Meyers, G. Heller, and J. Healey Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience J Clin Oncol 10 1992 5 15
2. S. Bielack, B. Kempf-Bielack, and G. Delling Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols J Clin Oncol 20 2002 776 790
3. G. Bacci, A. Longhi, and M. Versari Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution Cancer 106 2006 1154 1161
4. S. Bielack, H. Jürgens, and G. Jundt Osteosarcoma: the COSS experience Cancer Treat Res 152 2009 289 308
5. M.P. Link, A.M. Goorin, and A.W. Miser The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity New Engl J Med 314 1986 1600 1606
6. N. Jaffe, H. Carrasco, and A.K. Raymond Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 95 2002 2202 2210
7. S. Ferrari, S. Smeland, and M. Mercuri Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups J Clin Oncol 23 2005 8845 8852
8. R. Baumgart, S. Hinterwimmer, and M. Krammer The bioexpandable prosthesis: a new perspective after resection of malignant bone tumors in children J Pediatr Hematol Oncol 27 2005 452 455
9. G.A. Marulanda, E.R. Henderson, and D.A. Johnson Orthopedic surgery options for the treatment of primary osteosarcoma Cancer Control 15 2008 13 20
10. T.F. DeLaney, L. Park, and S.I. Goldberg Radiotherapy for local control of osteosarcoma Int J Radiat Oncol Biol Phys 61 2005 492 498
11. R. Schwarz, O. Bruland, and A. Cassoni The role of radiotherapy in osteosarcoma Cancer Treat Res 152 2009 147 165
12. S. Bielack, J.N. Machatschek, and S. Flege Delaying surgery with chemotherapy for osteosarcoma of the extremities Expert Opin Pharmacother 5 2004 1243 1256
13. N. Federman, N. Bernthal, and F.C. Eilber The multidisciplinary management of osteosarcoma Curr Treat Options Oncol 10 2009 82 93
14. I.J. Lewis, M.A. Nooij, and J. Whelan Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup J Natl Cancer Inst 99 2007 112 128
15. C.A. Stiller, S.S. Bielack, and G. Jundt Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project Eur J Cancer 42 2006 2124 2135
16. L. Mirabello, R.J. Troisi, and S.A. Savage Osteosarcoma incidence and survival rates from 1973 to 2004. Data from the Surveillance, Epidemiology, and End Results Program Cancer 115 2009 1531 1543
17. Carrle D, Bielack S, Sydes M, et al. The European and American osteosarcoma study group protocol EURAMOS-1: successful transatlantic cooperation in osteosarcoma. In: 15th Annual meeting of the connective tissue oncology society, November 5-7, Miami, FL, 2009 [abstract # 39452].
18. E.S. Kleinerman, S.F. Jia, and J. Griffin Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration J Clin Oncol 10 1992 1310 1316
19. European public assessment report for mepact, international nonproprietary name: mifamurtide, procedure no. EMEA/H/C/000802, published 06/05/09. Annex I, summary of product characteristics. Doc. Ref.: EMEA/CHMP/635781/2008.
20. IDM Pharma, Inc. (Nasdaq: IDMI) - News release - IDM Pharma's MEPACT® (Mifamurtide, L-MTP-PE) receives approval in Europe for treatment of patients with non-metastatic, resectable osteosarcoma. First new agent approved to treat osteosarcoma in more than 20 years, Irvine, California, March 9, 2009.
21. Takeda Pharmaceutical Company Limited (TSE: 4502) and IDM Pharma, Inc. (NASDAQ: IDMI): News release - Takeda to acquire IDM Pharma, adding MEPACT® (mifarmutide), the first treatment approved for osteosarcoma in more than 20 years, to its oncology franchise, Osaka, Japan, and Irvine, California, May 18, 2009.
22. Arbeitskreis DRG der DGHO: 2010-DGHO Nub Anträge im doc format version F3 und F4 stand 14.10.09. < http://www.dgho.de/informationen/ dokumente-der-arbeitskreise/arbeitskreis-drg-dokumentation-kodierung/ 2010-DGHO%20Nub%20Antraege%20im%20doc%20Format%20Version%20F3%20und%20F4%20Stan d%2014-10-09.zip >.
23. P.A. Meyers, C.L. Schwartz, and M. Krailo Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate J Clin Oncol 23 2005 2004 2011
24. P.A. Meyers, C. Schwartz, and M. Krailo Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children's Oncology Group J Clin Oncol 26 2008 633 638
25. J.L. Romet-Lemonne, B. Mills, and W.H. Fridman Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethanolamine in the treatment of osteosarcoma J Clin Oncol 23 2005 6437 6438
26. A.J. Chou, E.S. Kleinerman, and M.D. Krailo Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Cancer 115 2009 5339 5348
27. Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. J Clin Oncol 2008;26:3103-4 [author reply 3104-5].
28. Bielack S, Marina N, Ferrari S, et al. Osteosarcoma: the same old drugs or more? J Clin Oncol 2008;26:3102-3 [author reply 3104-5].
29. US Food and Drug Administration, Division of Biologic Oncology Products. Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Oncologic Drugs Advisory Committee: FDA briefing document, May 9, 2007. NDA 022092 mifamurtide (muramyl tripeptide phosphatidyl ethanolamine, MTP-PE) INT 0133 Cooperative Group Protocol. Immuno-Designed Molecules, Inc. (IDM Pharma, Inc.).